Ribopeutic

Executive Summary

Ribopeutic is a privately held Chinese biotechnology company founded in 2020 and headquartered in Hangzhou, focusing on RNA-based therapeutics for oncology and genetic diseases. The company leverages proprietary RNA technology platforms combined with innovative delivery systems to target previously undruggable pathways, addressing significant unmet medical needs. Currently in preclinical stage with an employee range of 10-50, Ribopeutic is developing a pipeline of novel therapies that exploit RNA biology for cancer treatment. With no disclosed funding or valuation, the company operates with a lean, research-intensive model typical of early-stage biotechs. As RNA therapeutics gain traction globally, Ribopeutic's approach could position it as a key player in China's burgeoning biotech sector, pending successful advancement of its lead programs into clinical development.

Upcoming Catalysts (preview)

• Q2 2027Lead program IND filing with China NMPA45% success
• H2 2026Preclinical efficacy data presentation at major oncology conference (e.g., ASCO or ESMO)60% success
• Q4 2026Strategic partnership or licensing deal for delivery technology platform35% success